Towards Effective, Patient-tailored Anti-plasma Cell Therapies in AL Amyloidosis: Predicting Drug Response and Overcoming Drug Resistance
NCT07585331
·
clinicaltrials.gov ↗
COMPLETED
Status
250
Enrollment
OTHER
Sponsor class
Conditions
AL Amyloidosis
Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia